ALTUVIIIO is a first-in-class, high-sustained factor VIII replacement therapy which provides highly effective bleed protection in adults and children with hemophilia A Approval demonstrates commitment ...
Uncertainty defined the conversation as FTR addressed the challenges facing the Class 8 market industry. “This is not the cycle you were planning for,” FTR CEO Jonathan Starks told attendees Monday at ...
While freight markets cooled in 2023, it didn’t stop fleets from ordering new equipment last year, as the Class 8 market saw a historically high level of order-board action over the year's final ...
Active ingredient: Antihemophilic Factor (recombinant): nominally 250 IU, 500 IU, 1,000 IU, or 2,000 IU per vial; powder for IV infusion after reconstitution; plasma/ albumin-free; preservative-free; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results